The ASTRO Active Motion Management (AMM) Model Policy was developed to define when CPT 77412 (Treatment Delivery with Active Motion Management) is appropriate and what documentation should support its use. Importantly, the policy is intended as a coverage model, not a clinical practice guideline. ASTRO explicitly states that final coverage decisions remain with individual health plans.
What is Active Motion Management (AMM)?
According to the policy, AMM is the real-time localization and tracking of a treatment target and/or organs at risk during radiation delivery. The key concept is that physiologic motion (typically respiratory motion) is continuously monitored and actively influences radiation delivery.
Examples include:
- Respiratory gating
- Real-time fiducial tracking
- Surface-guided systems only when they directly control beam delivery
- MRI-guided adaptive treatments with real-time beam management
- Breath-hold techniques tied directly to beam on/off decisions
The defining feature is that motion data must directly affect treatment delivery while the beam is on.
What DOES qualify as AMM?
ASTRO identifies several characteristics that distinguish true AMM:
- Continuous monitoring of target position throughout treatment
- Automatic or manual beam interruption when motion exceeds tolerance
- Beam resumes only after target returns within tolerance
- Real-time motion influences beam delivery every fraction
- Motion management occurs during treatment delivery, not simply before treatment.
What does NOT qualify?
ASTRO is equally clear about what is not Active Motion Management.
The following alone do not qualify:
- Patient setup
- CBCT performed before treatment
- Standard image guidance
- Passive surface monitoring
- Immobilization devices
- Verification imaging performed only before beam-on
- Monitoring that does not influence radiation delivery in real time.
This distinction is particularly important because many technologies marketed as “motion management” do not meet the definition required for CPT 77412.
Indications for AMM
ASTRO identifies clinical situations where AMM is generally appropriate because physiologic motion can compromise target localization or normal tissue sparing.
Examples include:
- Lung tumors
- Liver tumors
- Pancreas
- Breast DIBH
- Certain upper abdominal tumors
- Selected prostate treatments
- Patients with anticipated intrafraction motion due to neurologic or behavioral conditions.
Prostate-Specific Guidance
The prostate section is frequently misunderstood.
ASTRO does not state that all prostate treatments qualify for Active Motion Management.
Instead, the model policy specifically describes prostate AMM as:
Intrafraction tracking of fiducial markers using triggered imaging with beam gating or interruption tied to the tracked position in real time.
That language establishes several requirements.
For prostate, AMM should include:
- Continuous intrafraction monitoring
- Fiducial-based localization (or equivalent validated target tracking)
- Real-time detection of prostate movement
- Automatic or manual interruption of radiation delivery when motion exceeds tolerance
- Resumption of treatment only after acceptable repositioning
Simply obtaining:
- CBCT,
- kV imaging,
- pre-treatment alignment,
- SGRT setup,
- periodic imaging,
does not satisfy ASTRO’s definition of AMM because these activities do not actively modify beam delivery during treatment.
Documentation Requirements
ASTRO recommends documentation include:
- Medical necessity for AMM
- Technology used
- Motion thresholds and tolerances
- How motion is monitored
- How beam interruption occurs
- How motion data are reviewed during treatment
- Beam control methodology.
Important Reimbursement Considerations
Perhaps the most important takeaway is that ASTRO’s document is a model policy—not an authoritative reimbursement standard.
The policy itself states:
- It is not intended to serve as a clinical guideline.
- It reflects what ASTRO believes are generally accepted professional standards.
- Final coverage decisions remain subject to the patient’s health plan and payer policies.
As a result:
- Commercial payers are not obligated to adopt ASTRO’s recommendations.
- Medicare Administrative Contractors (MACs) establish their own Local Coverage Determinations (LCDs) and billing guidance.
- Individual commercial insurers may apply more restrictive definitions, require prior authorization, or decline payment despite compliance with the ASTRO model policy.
This distinction is particularly relevant for prostate cancer, where many practices utilize intrafraction imaging or surface guidance. Unless the technology actively controls or interrupts beam delivery in real time based on prostate motion, some payers may determine that the requirements for CPT 77412 have not been met—even if ASTRO considers the workflow clinically appropriate.